🔍

Kerala Ayurveda Ltd (530163)

📊 NSE: 530163 🏢 Pharmaceuticals 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

Kerala Ayurveda to Merge Profitable WOS Ayurvedagram; Subsidiary PAT at ₹3.16 Cr

🟢 POSITIVE ⭐ 7/10

M&A 📅 12 Aug 2026, 07:19 PM

Kerala Ayurveda's board has approved the amalgamation of its wholly-owned subsidiary (WOS), Ayurvedagram Heritage Wellness Centre, into the parent company. The subsidiary is notably profitable, reporting a PAT of ₹3.16 Cr on a turnover of ₹15.47 Cr for FY26, which will help offset the parent's standalone losses of ₹14.74 Cr. The merger involves no share issuance or cash consideration as it is a 100% subsidiary. Additionally, the company granted 64,875 ESOPs at an exercise price of ₹10 and re-appointed Mr. Ramesh Vangal as a Director.

Subsidiary turnover of ₹15.47 Cr represents approximately 18% of the parent's standalone FY26 revenue of ₹85.48 Cr
Subsidiary reported a PAT of ₹3.16 Cr for FY26, while the parent company recorded a standalone loss of ₹14.74 Cr
Subsidiary Net Worth stands at ₹16.23 Cr as of March 31, 2026, compared to the parent's ₹36.15 Cr
Grant of 64,875 ESOPs at an exercise price of ₹10 per share, significantly below the current market price of ₹155.8
The merger is subject to NCLT and shareholder approvals with no change in the shareholding pattern

💡 Investors should monitor the timeline for NCLT approval and the subsequent impact on standalone profitability and debt-servicing capability once the profitable subsidiary is absorbed.

16% Revenue Growth in Q1 FY27; Kerala Ayurveda Targets Rs 1,000 Cr Revenue by FY30

🔵 WATCH ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 07:11 PM

Kerala Ayurveda reported Q1 FY27 consolidated revenue of 33.2 Cr, a 16% YoY increase, while narrowing its operating EBITDA loss to 3.82 Cr from 7.10 Cr in the previous quarter. Despite topline growth, the company posted a net loss of 8.08 Cr, significantly impacted by a 5x surge in promoter loan interest costs. Management reaffirmed its 'Vision 2030' to scale revenue to 1,000 Cr and expects monthly operating EBITDA breakeven by September 2026. The company is also planning to convert promoter loans to equity to improve its high debt-to-equity ratio, which currently stands at 7.82.

Consolidated revenue grew 16% YoY to 33.2 Cr in Q1 FY27, led by a 28.3% growth in standalone operations.
Operating EBITDA (Adj.) loss reduced by ~50% sequentially to 3.82 Cr from 7.10 Cr in Q4 FY26.
India D2C e-commerce segment grew 38.9% YoY, with repeat customer contribution rising to 33%.
US Wellness Clinic revenue surged 81.9% YoY, offsetting an 8.2% decline in the US Academy segment.
Vision 2030 targets a 10x revenue increase from 100 Cr in FY24 to 1,000 Cr by FY30.

💡 Monitor the achievement of the September 2026 monthly EBITDA breakeven target and the execution of the promoter loan-to-equity conversion in H2 FY27. Investors should also track the launch of the Karwar resort in October 2026 and the new premium brand in November 2026 as key growth drivers.

Kerala Ayurveda to Merge Profitable Rs 15.47 Cr WOS; Grants 64,875 ESOPs

🟢 POSITIVE ⭐ 7/10

M&A 📅 12 Aug 2026, 07:06 PM

Kerala Ayurveda's board has approved the merger of its wholly-owned subsidiary, Ayurvedagram Heritage Wellness Centre, into the parent company to streamline operations and eliminate duplicative costs. The subsidiary is profitable, reporting a PAT of Rs 3.16 Cr on a turnover of Rs 15.47 Cr for FY26, which will support the parent company that reported a loss of Rs 14.74 Cr in the same period. Additionally, the company granted 64,875 ESOPs at an exercise price of Rs 10 per share and recommended the re-appointment of Mr. Ramesh Vangal as a Non-Executive Director.

Approved merger of Ayurvedagram Heritage Wellness Centre (FY26 Turnover: Rs 15.47 Cr) with Kerala Ayurveda Ltd
Subsidiary Ayurvedagram reported a profit of Rs 3.16 Cr for FY26, contrasting with the parent's standalone loss of Rs 14.74 Cr
Grant of 64,875 ESOPs under the 2023 Plan at a deeply discounted exercise price of Rs 10 per share
Subsidiary Net Worth of Rs 16.23 Cr to be integrated, significantly impacting the parent's standalone Net Worth of Rs 36.15 Cr (as per filing)
Re-appointment of Mr. Ramesh Vangal, former Chairman of Seagram Asia Pacific, as Non-Executive Director

💡 Investors should monitor the NCLT approval timeline for the merger and observe if the consolidation of the profitable wellness unit helps stabilize the parent company's overall negative OPM (-13.5%).

Kerala Ayurveda to Merge Profitable Subsidiary Ayurvedagram; Grants 64,875 ESOPs

🟢 POSITIVE ⭐ 7/10

M&A 📅 12 Aug 2026, 03:50 PM

Kerala Ayurveda Ltd has approved the merger of its wholly-owned subsidiary, Ayurvedagram Heritage Wellness Centre, into itself to consolidate operations and reduce administrative costs. For FY26, the subsidiary was profitable with a PAT of ‹3.16 Cr on a turnover of ‹15.47 Cr, while the parent company reported a loss of ‹14.74 Cr. The board also approved Q1 FY27 results and granted 64,875 ESOPs at an exercise price of ‹10. The company remains highly leveraged with a debt-to-equity ratio of 7.82.

Ayurvedagram subsidiary reported FY26 turnover of ‹15.47 Cr and a profit of ‹3.16 Cr.
Parent company Kerala Ayurveda reported a loss of ‹14.74 Cr on a turnover of ‹85.48 Cr for FY26.
Grant of 64,875 ESOPs at an exercise price of ‹10 per share, significantly below the current market price of ‹157.3.
The merger will result in no change to the shareholding pattern as the transferor is a 100% subsidiary.
Subsidiary net worth of ‹16.23 Cr will be consolidated into the parent's ‹36.15 Cr net worth (as of March 2026).

💡 Investors should monitor the NCLT approval timeline for the merger and evaluate the Q1 FY27 consolidated results to see if the profitable subsidiary's performance can meaningfully offset parent-level losses.

Rs 15.47 Cr turnover subsidiary to merge with Kerala Ayurveda; 64,875 ESOPs granted

🟢 POSITIVE ⭐ 7/10

M&A 📅 12 Aug 2026, 03:40 PM

Kerala Ayurveda's board has approved the merger of its wholly-owned subsidiary, Ayurvedagram Heritage Wellness Centre, into the parent company. This is a significant consolidation as the subsidiary is profitable, reporting a PAT of Rs 3.16 Cr in FY26, whereas the parent company reported a standalone loss of Rs 14.74 Cr. The merger will also bring the subsidiary's Rs 16.23 Cr net worth onto the parent's balance sheet, which currently has a high debt-to-equity ratio of 7.82. Additionally, the board granted 64,875 ESOPs at an exercise price of Rs 10 per share and approved Q1 FY27 results.

Merger of Ayurvedagram Heritage Wellness Centre (FY26 turnover: Rs 15.47 Cr) into Kerala Ayurveda Ltd.
Subsidiary reported a profit of Rs 3.16 Cr for FY26, compared to the parent's standalone loss of Rs 14.74 Cr.
Subsidiary net worth of Rs 16.23 Cr will bolster the parent's thin net worth of Rs 11 Cr.
Grant of 64,875 ESOPs at an exercise price of Rs 10, a deep discount to the current market price of Rs 157.3.
Re-appointment of Mr. Ramesh Vangal as Non-Executive Director recommended for the upcoming AGM on September 28, 2026.

💡 Watch for the NCLT approval timeline for the merger and monitor if the integration of the profitable wellness center helps offset the parent company's operational losses in upcoming quarters.

Aug 12 Board Meeting to consider Q1 FY27 results for Kerala Ayurveda Ltd

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 06 Aug 2026, 04:43 PM

Kerala Ayurveda Ltd has scheduled a board meeting on August 12, 2026, to approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is currently under significant financial pressure, reporting a TTM net loss of ₹16 crore and a high Debt-to-Equity ratio of 7.82. Investors will be monitoring these results for any signs of operational turnaround following a ₹7.39 crore loss in the March 2026 quarter. The trading window for insiders has been closed since June 30, 2026.

Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results.
Trading window for designated persons closed from June 30, 2026, until 48 hours post-announcement.
Company reported a TTM revenue of ₹131 crore with a negative operating margin of -13.5%.
Net worth stands at a thin ₹11 crore against a total debt of ₹86 crore as per latest context.

💡 Watch for the financial results on August 12 to see if the company can narrow its losses and improve its operating cash flow to service its high debt load.

View All 530163 Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Not disclosed in available documents; however, the company transitioned from cumulative losses of INR 32.61 Cr (FY 2006-07 to FY 2012-13) to cumulative profits of INR 12.39 Cr (FY 2013-14 to FY 2017-18).

Geographic Revenue Split

Not disclosed in available documents, but operations are split between India (Kerala, Bangalore) and the USA (Milpitas, CA).

Profitability Margins

Cumulative profits of INR 12.39 Cr earned from FY 13-14 to FY 17-18, marking a recovery from previous cumulative losses of INR 32.61 Cr.

Capital Expenditure

Not disclosed in available documents, but assets include 8.50 acres at Manyali for Ayurvedagram Resort and 4 acres in Kerala for a new factory.

Credit Rating & Borrowing

The Katra Group provided an interest-free loan that peaked at INR 53.45 Cr in FY 2012-13. The waived interest value is estimated at INR 47.88 Cr based on a notional 10% simple interest rate.

⚙️ Operational Drivers

Raw Materials

Raw drugs, herbs, and traditional oils used for Ayurvedic formulations and treatments.

Import Sources

Sourced primarily from Kerala, India, including the Raw Drug Division in Kottai, Nedumbassery.

Capacity Expansion

Planned expansion includes a new factory on a 4-acre land parcel in Kerala and the development of Ayurvedagram Wellness Resorts (30 to 100 keys) via a JV with Sanghvi Brands.

Manufacturing Efficiency

Severely impacted by the 2018 floods, requiring extraordinary efforts for repair and refurbishment of units in Aluva and Nedumbassery.

📈 Strategic Growth

Expected Growth Rate

65%

Growth Strategy

Growth will be achieved through a Joint Venture with Sanghvi Brands Ltd to develop global Ayurvedagram Wellness Resorts, expansion of the US Academy (over 2,000 alumni), and the launch of new patented formulations (K-Series).

Products & Services

Ayurvedic medicines (Liposem+, Glymin+, Chyavanaprash, Myaxil), wellness services (Panchakarma, bodywork treatments), and educational certifications (Ayurvedic Wellness Counselor/Practitioner).

Brand Portfolio

Kerala Ayurveda, Ayurvedagram, KALPAM, Renovel Discoveries.

New Products/Services

New product launches include Liposem+, Glymin+, Cottage Products, and Lutein-based Eye Care products.

Market Expansion

Expansion into global markets (USA, Middle East, Indian Ocean) through a JV with Sanghvi Brands to operate Ayurvedic Spas in luxury hotels like Ritz Carlton and JW Marriott.

Strategic Alliances

Joint Venture with Sanghvi Brands Ltd; MoU with Benares Hindu University (BHU) for research and education; JV with Renovel Discoveries Inc (US).

🌍 External Factors

Industry Trends

The wellness industry is a $1 trillion opportunity; the complementary/alternative medicine sector grew 65% to $187 billion, driven by a desire for nature-based remedies.

Competitive Landscape

Competes in the luxury wellness and spa market alongside global brands like L'Occitane, Elemis, and Warren Tricomi.

Competitive Moat

Durable advantages include 130 man-years of scientific expertise, BHU research alliance, and accreditation from the States of California and Washington for its US Academy.